This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

EVT 101

Evotec AG

Drug Names(s): EVT 101

Description: EVT 101 is a highly potent and selective antagonist of NR2B subunit containing NMDA receptors. The NR2B subunit is found primarily in the forebrain. The relatively low affinity NMDA receptor antagonist Namenda has shown efficacy in Alzheimer's disease; however, this class of drugs has been difficult to develop due to side effects. It is hoped that selective NR2B antagonists will help avoid side effects, though some of these agents have had issues with cardiac arrhythmias. The mechanism of action of NMDA antagonism in Alzheimer disease is not clearly understood, though it could involve reducing glutamate overstimulation and toxicity.

Deal Structure: In March 2004, Evotec announced that it has acquired from Roche an exclusive worldwide license to develop and market an extensive patent portfolio covering NMDA receptor NR2B subtype selective antagonists for the treatment of a variety of CNS disorders. Roche has retained rights to reacquire the compounds in the future. Financial details of the collaboration were not disclosed.

In November 2006, Roche did not opt in after Phase I, however, expressed continued interest in further option rights after proof-of-concept (after period end).

In March 2009, Evotec and Roche announced that they entered into an agreement for Phase II clinical development of EVT 101 in patients with treatment-resistant depression.

In December 2012, Evotec announced that it has entered into a license agreement with Janssen Pharmaceuticals. Under the terms of this agreement Janssen has been granted an exclusive, worldwide license to a series of small molecule drug candidates. Janssen has the...See full deal structure in Biomedtracker

Partners: Roche Holding AG Johnson & Johnson


EVT 101 News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug